Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients

Hyo Jae Kang, Jong Sun Park, Dong Wan Kim, Jinwoo Lee, Yun Jeong Jeong, Sun Mi Choi, Sang Min Lee, Seok Chul Yang, Chul Gyu Yoo, Young Whan Kim, Sung Koo Han, Jae Joon Yim

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Background: The incidence and clinical characteristics of adverse pulmonary reactions resulting from anticancer monoclonal antibody (mAbs) therapy have not been well described. We determined the incidence and clinical characteristics of adverse pulmonary reactions in patients treated with anticancer chemotherapy including mAbs. Methods: A retrospective cohort study was performed including patients who were treated with a chemotherapeutic regimen that included rituximab, trastuzumab, cetuximab, or bevacizumab at Seoul National University Hospital between January 1, 2004 and December 31, 2008. Rates of adverse pulmonary reactions classified as non-infectious and infectious complications were compared with those among patients treated with comparable regimens without mAbs. Results: In total, 1078 patients were included (418 for rituximab, 329 for trastuzumab, 122 for cetuximab, 209 for bevacizumab). Adverse pulmonary reactions were identified in 36 patients (3.5%) and the incidence differed among agents: cetuximab (9%), rituximab (5.3%), trastuzumab (0.6%), bevacizumab (0.5%). Infectious pulmonary complications occurred in 28 patients, and eight patients experienced non-infectious pulmonary complications, most commonly interstitial lung disease (6 patients). In a multivariate analysis, low serum albumin level was associated with the development of pulmonary complications. The incidence of overall adverse pulmonary reactions did not differ between the mAbs users and the 1012 patients treated with comparable regimens other than mAbs (3.5% vs. 2.8%, P = 0.53). Conclusions: Infectious and non-infectious adverse pulmonary reactions occur in patients with cancer who are administered a regimen including mAbs. Clinicians should be alert for the possibility of pulmonary adverse reactions, particularly among patients with low serum albumin levels.

Original languageEnglish
Pages (from-to)443-450
Number of pages8
JournalRespiratory Medicine
Volume106
Issue number3
DOIs
StatePublished - Mar 2012

Keywords

  • Adverse pulmonary reaction
  • Anticancer chemotherapy
  • Bevacizumab
  • Cetuximab
  • Rituximab
  • Trastuzumab

Fingerprint

Dive into the research topics of 'Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients'. Together they form a unique fingerprint.

Cite this